Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
2019 · Annals of Oncology · 238 citations
https://doi.org/10.1093/annonc/mdz398
S
Silvia Martin Lluesma
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
26
Papers
1.2K
Citations
11
h-index
12
i10-index
Silvia Martin Lluesma is an academic researcher. The author has contributed to research in topics: Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 11, co-authored 23 publications.
ORCID: 0000-0001-7491-1876Papers by this author
worksA Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
2019 · Journal of Translational Medicine · 59 citations
https://doi.org/10.1186/s12967-019-02133-w
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors
2024 · Nature Communications · 6 citations
https://doi.org/10.1038/s41467-024-53265-7
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
2025 · Annals of Oncology · 4 citations
https://doi.org/10.1016/j.annonc.2025.04.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat